AC Immune (NASDAQ: ACIU) and Mesoblast (NASDAQ:MESO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.
This is a breakdown of recent ratings and price targets for AC Immune and Mesoblast, as reported by MarketBeat.com.
||Strong Buy Ratings
AC Immune presently has a consensus target price of $16.00, indicating a potential upside of 68.24%. Mesoblast has a consensus target price of $15.00, indicating a potential upside of 141.55%. Given Mesoblast’s stronger consensus rating and higher probable upside, analysts clearly believe Mesoblast is more favorable than AC Immune.
This table compares AC Immune and Mesoblast’s net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Earnings and Valuation
This table compares AC Immune and Mesoblast’s gross revenue, earnings per share and valuation.
||Earnings Per Share
AC Immune has higher revenue and earnings than Mesoblast. AC Immune is trading at a lower price-to-earnings ratio than Mesoblast, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
AC Immune has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Mesoblast has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500.
Institutional and Insider Ownership
19.5% of AC Immune shares are held by institutional investors. Comparatively, 2.9% of Mesoblast shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Mesoblast beats AC Immune on 8 of the 14 factors compared between the two stocks.
AC Immune Company Profile
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms generates antibodies and small molecules that selectively bind to misfolded proteins to address neurodegenerative indications, such as Alzheimer's (AD), Parkinson's, down syndrome, and glaucoma diseases. The company's lead product candidate is crenezumab, a humanized, monoclonal, and conformation-specific anti-Abeta antibody, which is in Phase 3 clinical studies. It also engages in developing ACI-24, a vaccine candidate that is in a combined Phase 1/2a clinical study for AD; and ACI-35, a vaccine candidate against phosphorylated pathological tau and is currently in Phase 1b clinical testing in patients with mild to moderate AD. In addition, the company develops PET ligands that are tracers to target tau and alpha-synuclein aggregates. It has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Piramal Imaging; and Biogen International GmbH. AC Immune SA was founded in 2003 and is headquartered in Lausanne, Switzerland.
Mesoblast Company Profile
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.
Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.